Celgene Raises Revlimid Price Across The Board
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm says the increases reflect inflation, cost of patient assistance and RevAssist risk management programs.
You may also be interested in...
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Celgene Commences Thalomid Patent Litigation Against Barr
Lawsuit triggers 30-month stay of FDA action on generic thalidomide.